STOCK TITAN

MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MEI Pharma will participate in the H.C. Wainwright Global Investment Conference 2022, presenting a company overview and business update starting May 24, 2022, at 7:00 a.m. Eastern Time. The presentation will be available for on-demand listening for 90 days. MEI Pharma focuses on developing innovative therapies for cancer, with its clinical-stage assets including zandelisib, which is under FDA review. Interested parties can access the presentation on MEI Pharma's website.

Positive
  • None.
Negative
  • None.

SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will present a company overview and business update available for on-demand listening starting Tuesday, May 24, 2022, 7:00 a.m. Eastern Time that will be archived for 90 days.

The presentation can be accessed via the Events & Presentations page of the Investors section of MEI Pharma's website at https://www.meipharma.com/investors/events-calendar. An archived replay of the webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.

Forward-Looking Statements

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the results of our clinical trials of zandelisib, the anticipated timing of our submission of an FDA marketing application for zandelisib, the anticipated timing of the disclosure of the final study data for our Phase 2 TIDAL trial, the timing and success of enrollment for our Phase 3 COASTAL trial, our projected financial position and our expected cash runway, the overall advancement of our product candidates in clinical trials and our plans to continue development of our product candidates. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; the availability or appropriateness of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; costs and delays in the development and/ or FDA approval of our product candidates, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the risk that our clinical trials are discontinued or delayed for any reason, including for safety, tolerability, enrollment, manufacturing or economic reasons; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI Pharma, Inc.

David A. Walsey

Tel: 858-369-7104

investor@meipharma.com

Jason I. Spark

Canale Communications for MEI

Tel: 619-849-6005

jason.spark@canalecomm.com

Source: MEI Pharma, Inc.

FAQ

What is the date and time of MEI Pharma's presentation at the H.C. Wainwright Global Investment Conference 2022?

MEI Pharma's presentation will begin on May 24, 2022, at 7:00 a.m. Eastern Time.

How long will MEI Pharma's presentation be available for on-demand listening?

The presentation will be available for on-demand listening for 90 days.

What is zandelisib and its significance in MEI Pharma's portfolio?

Zandelisib is a clinical-stage asset being developed by MEI Pharma, aimed at advancing therapies for cancer and is currently under FDA review.

Where can I access MEI Pharma's presentation from the conference?

You can access the presentation on MEI Pharma's website.

Is there a replay of MEI Pharma's investment conference presentation?

Yes, an archived replay of the webcast will be available for at least 30 days after the live event concludes.

MEI Pharma, Inc.

NASDAQ:MEIP

MEIP Rankings

MEIP Latest News

MEIP Stock Data

16.33M
6.58M
1.31%
41.04%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO